Aminoazacyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
申请人:Wyeth LLC
公开号:US07939520B2
公开(公告)日:2011-05-10
The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.
本发明提供了一种I式化合物及其在治疗与5-HT6受体相关或受其影响的疾病中的用途。
5-Cyclic Amine-3-arylsulfonylindazoles as Novel 5-HT<sub>6</sub> Receptor Antagonists
作者:Simon N. Haydar、Heedong Yun、Patrick M. Andrae、James Mattes、Jean Zhang、Angela Kramer、Deborah L. Smith、Christine Huselton、Radka Graf、Suzan Aschmies、Lee E. Schechter、Thomas A. Comery、Albert J. Robichaud
DOI:10.1021/jm901674f
日期:2010.3.25
Novel 5-cyclic amine-3-arylsulfonylindazoles were prepared, and several analogues within this class have been identified as high-affinity 5-HT6 receptor ligands with improved pharmacokinetic and pharmacological properties. One selected example, 18b, showed good brain penetrability and a generally favorable pharmacokinetic profile with procognitive efficacy in the rat novel object recognition assay. The synthesis and structure activity relationship of this potent class are discussed.
AMINOAZACYCLYL-3-SULFONYLINDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
申请人:Haydar Simon Nicolas
公开号:US20080293688A1
公开(公告)日:2008-11-27
The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.